| Property | Value |
|---|
|
?:abstract
|
-
Severe Acute Respiratory Syndrome related coronaviruses -2 (SARS CoV-2) infection posed unprecedented challenges to the world SARS Co-V 2 shows similarity with severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) and are distributed broadly among humans and animals and cause respiratory tract infections It is imperative for identifying appropriate therapeutic options in response to the SARC CoV-2 outbreak Here, we discuss the potential drug options for repurposing against Corona Virus Disease 2019 (COVID-19)/SARS-CoV-2 COVID-19 outbreak has emphasized the urgent need for repurposing drugs We focus here on the existing drugs, based on therapeutic application in influenza and human coronaviruses: SARS and MERS Hydroxychloroquine (HCQ) has a long-standing history in the prevention and treatment of malaria and has immunomodulatory effects used in various autoimmune disease Multiple research studies show that HCQ improved virologic clearance, and a combination of HCQ with Azithromycin (AZ) is better in viral clearance These drugs are relatively safe and may improve the clinical outcome in the patient
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:journal
|
-
Indian_Journal_of_Basic_and_Applied_Medical_Research
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:source
|
|
|
?:title
|
-
Repurposing of hydroxychloroquine (HCQ) and azithromycin in prophylaxis and treatment of COVID-19 disease
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}